ZimVie Announces Publication of a Study Supporting the Benefits of Its Implant Surface Technologies
ZimVie Inc. (NASDAQ: ZIMV) announced the publication of a scientific study in the Journal of Biomedical Materials Research demonstrating the advantages of their dental implant surface technology. The study compared ZimVie's T3® PRO and TSX® Implants' dual acid-etched coronal surface technology with other leading implant brands.
The research identified a critical threshold roughness for dental implants, below which bacterial adhesion remains similar to smooth machined surfaces. ZimVie's implants' coronal surfaces, DAE and Osseotite®, are engineered around this threshold, showing bacterial adhesion levels comparable to machined surfaces while maintaining crestal bone levels similar to rougher surfaces.
The findings suggest that ZimVie's implants may help reduce the risk of peri-implant infections compared to other commercial implants, addressing the growing concern of peri-implant mucositis and peri-implantitis in dental implantology.
ZimVie Inc. (NASDAQ: ZIMV) ha annunciato la pubblicazione di uno studio scientifico nel Journal of Biomedical Materials Research che dimostra i vantaggi della loro tecnologia di superficie per impianti dentali. Lo studio ha confrontato la tecnologia della superficie coronale a doppio trattamento acido degli impianti T3® PRO e TSX® di ZimVie con altri marchi leader di impianti.
La ricerca ha identificato una soglia critica di rugosità per gli impianti dentali, al di sotto della quale l'adesione batterica rimane simile a quella delle superfici levigate. Le superfici coronali degli impianti di ZimVie, DAE e Osseotite®, sono progettate attorno a questa soglia, mostrando livelli di adesione batterica comparabili a quelli delle superfici levigate, mantenendo al contempo livelli di osso crestal simili a quelli delle superfici più ruvide.
I risultati suggeriscono che gli impianti di ZimVie potrebbero contribuire a ridurre il rischio di infezioni peri-impiantari rispetto ad altri impianti commerciali, affrontando la crescente preoccupazione per la mucosite peri-implantare e la peri-implantite nella implantologia dentale.
ZimVie Inc. (NASDAQ: ZIMV) anunció la publicación de un estudio científico en el Journal of Biomedical Materials Research que demuestra las ventajas de su tecnología de superficie de implantes dentales. El estudio comparó la tecnología de superficie coronaria grabada con ácido dual de los implantes T3® PRO y TSX® de ZimVie con otras marcas líderes de implantes.
La investigación identificó un umbral crítico de rugosidad para los implantes dentales, por debajo del cual la adhesión bacteriana se mantiene similar a la de superficies mecanizadas suaves. Las superficies coronales de los implantes de ZimVie, DAE y Osseotite®, están diseñadas en torno a este umbral, mostrando niveles de adhesión bacteriana comparables a los de las superficies mecanizadas, mientras mantienen niveles de hueso crestal similares a los de superficies más rugosas.
Los hallazgos sugieren que los implantes de ZimVie pueden ayudar a reducir el riesgo de infecciones peri-implantarias en comparación con otros implantes comerciales, abordando la creciente preocupación por la mucositis peri-implantaria y la peri-implantitis en implantología dental.
짐비(ZimVie Inc.) (NASDAQ: ZIMV)는 생체재료 연구 저널(Journal of Biomedical Materials Research)에 임플란트 표면 기술의 장점을 보여주는 과학 연구 결과를 발표했다고 전했습니다. 이 연구는 짐비의 T3® PRO 및 TSX® 임플란트의 이중 산 에칭 처리된 관상 표면 기술을 다른 주요 임플란트 브랜드와 비교했습니다.
연구에서는 치과 임플란트의 중요한 임계 거칠기 수준을 확인했으며, 이 수준 아래에서는 박테리아 부착이 매끄럽게 가공된 표면과 유사함을 나타냈습니다. 짐비 임플란트의 관상 표면인 DAE와 오세오타이트(Osseotite®)는 이 임계값을 기반으로 설계되어, 가공된 표면과 유사한 박테리아 부착 수준을 보이면서도 거친 표면과 유사한 크리스탈 뼈 수준을 유지합니다.
이 결과는 짐비의 임플란트가 상업적인 다른 임플란트에 비해 peri-implant 감염 위험을 줄이는 데 도움이 될 수 있음을 시사하며, 치과 임플란트학에서 증가하는 peri-implant 점막염 및 peri-implantitis 문제를 다루고 있습니다.
ZimVie Inc. (NASDAQ: ZIMV) a annoncé la publication d'une étude scientifique dans le Journal of Biomedical Materials Research démontrant les avantages de sa technologie de surface des implants dentaires. L'étude a comparé la technologie de surface coronale à double gravure acide des implants T3® PRO et TSX® de ZimVie avec d'autres marques d'implants leaders.
La recherche a identifié un seuil critique de rugosité pour les implants dentaires, en dessous duquel l'adhésion bactérienne reste similaire à celle des surfaces usinées lisses. Les surfaces coronales des implants de ZimVie, DAE et Osseotite®, sont conçues autour de ce seuil, montrant des niveaux d'adhésion bactérienne comparables à ceux des surfaces usinées, tout en maintenant des niveaux d'os crête similaires à ceux des surfaces plus rugueuses.
Les résultats suggèrent que les implants de ZimVie pourraient aider à réduire le risque d'infections péri-implantaires par rapport à d'autres implants commerciaux, abordant ainsi la préoccupation croissante concernant la mucosite péri-implantaire et la péri-implantite en implantologie dentaire.
ZimVie Inc. (NASDAQ: ZIMV) hat die Veröffentlichung einer wissenschaftlichen Studie im Journal of Biomedical Materials Research angekündigt, die die Vorteile ihrer Oberflächen-Technologie für Zahnimplantate demonstriert. Die Studie verglich die doppelt säuregeätzte Kronenoberflächen-Technologie der T3® PRO und TSX® Implantate von ZimVie mit anderen führenden Implantatmarken.
Die Forschung identifizierte einen kritischen Schwellenwert von Rauheit für Zahnimplantate, unterhalb dessen die bakterielle Anhaftung ähnlich der glatten bearbeiteten Oberflächen bleibt. Die Kronenoberflächen der ZimVie-Implantate, DAE und Osseotite®, sind um diesen Schwellenwert herum konzipiert und zeigen bakterielle Anhaftungsniveaus, die mit denen bearbeiteter Oberflächen vergleichbar sind, während sie ähnliche Krestal-Knochenlevels wie rauere Oberflächen aufrechterhalten.
Die Ergebnisse deuten darauf hin, dass die Implantate von ZimVie das Risiko von peri-implantären Infektionen im Vergleich zu anderen kommerziellen Implantaten verringern könnten und damit die wachsende Sorge um peri-implantäre Mukositis und Peri-Implantitis in der Zahnimplantologie adressieren.
- Surface technology demonstrates lower risk of peri-implant infections
- Implants achieve optimal balance between bacterial resistance and bone maintenance
- Scientific validation published in leading journal supports product effectiveness
- None.
Insights
This peer-reviewed study publication represents a significant technical and commercial validation for ZimVie's premium dental implant portfolio. The research demonstrates a important engineering achievement - their proprietary surface treatment technology hits an optimal 'Goldilocks zone' of surface roughness that few competitors have achieved.
The market implications are substantial. Peri-implant infections affect up to 47% of implant patients within 5 years, representing one of the biggest challenges in modern dental implantology. By engineering implant surfaces that resist bacterial adhesion while maintaining strong bone integration, ZimVie addresses a major unmet need that could help drive market share gains in the $5+ billion global dental implant market.
Key competitive advantages validated by this study include:
- Lower risk of costly implant failures and complications
- Reduced need for antibiotic treatments
- Better long-term aesthetic outcomes
- Potential for improved reimbursement positioning
This research also validates ZimVie's strategic focus on premium, technology-differentiated products rather than competing purely on price. With dental implant procedures growing 12-15% annually as populations age, having demonstrably superior technology could help ZimVie capture a larger share of this expanding market while maintaining premium pricing.
Data confirms ZimVie implants meet critical roughness criteria advantageous for long-term peri-implant health
PALM BEACH GARDENS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced the publication of a detailed scientific study demonstrating the surface texture of ZimVie’s premium implants may help to lower the risk of peri-implant infections when compared to other commercially available implants.
The study, titled “The Role of Implant Coronal Surface Properties on Early Adhesion of Streptococcus Oralis—An In Vitro Comparative Study,” has been published in the Journal of Biomedical Materials Research, a leading journal in the field of biological and medical sciences. The study evaluated the innovative dual acid-etched coronal surface technology of ZimVie’s T3® PRO and TSX® Implants against other leading implant brands.
In dental implantology, rough surfaces at the top of the implant, designed to maintain crestal bone levels, may also promote bacterial adhesion. This potentially leads to soft tissue inflammation and peri-implant bone loss, jeopardizing long-term implant success. The new data reveals a critical threshold roughness, above which bacterial adhesion increases significantly, while below that, bacterial adhesion profiles remain comparable to smooth machined surfaces. ZimVie’s implants’ coronal surfaces, DAE and Osseotite®, have been engineered around this threshold. These surfaces not only exhibit bacterial adhesion levels comparable to machined surfaces but also demonstrate crestal bone maintenance akin to rougher surfaces.*
“The prevalence of peri-implant mucositis (inflammation) and peri-implantitis has been on the rise in recent decades,” said Hai Bo Wen, Research Director at ZimVie. “We have always been committed to the highest standards of quality and patient safety and are proud that ZimVie’s Contemporary Hybrid Surface technologies have demonstrated success in helping mitigate this concern in today’s dental implantology field.”
About TSX Implants
Launched in 2022, TSX Implants are designed for immediate extraction and standard loading protocols as well as placement predictability and primary stability in soft and dense bone. The Implant incorporates features with more than two decades of real-world, clinical data to deliver peri-implant health, crestal bone maintenance, long-term osseointegration, and prosthetic stability,* including the Contemporary Hybrid Surface combination with coronal DAE. Integrated with ZimVie’s end-to-end digital workflows and engineered with surgical and restorative versatility, the TSX Implant furthers ZimVie’s commitment to simplify procedures and optimize practice protocols.
About T3 PRO Implants
Launched in 2022, the T3 PRO Implant’s advanced design delivers high primary stability and allows for immediate function. T3 PRO has a hybrid surface featuring the proprietary Osseotite surface on the implant collar, as well as a rougher grit-blasted implant body. Not only have multiple long-term, independent clinical studies on the proprietary Osseotite surface demonstrated safety and performance,* they have also demonstrated the effect of this surface in preserving crestal bone. This Contemporary Hybrid Surface of T3 PRO along with the optional integrated platform switching design has also been shown to provide early and long-term peri-implant bone support.
* References on file at ZimVie.
About ZimVie
ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning ZimVie’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. For a list and description of some of such risks and uncertainties, see ZimVie’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in ZimVie’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and ZimVie disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.
Media Contact Information:
ZimVie
Grace Flowers • Grace.Flowers@ZimVie.com
(561) 319-6130
Investor Contact Information:
Gilmartin Group LLC
Webb Campbell • Webb@gilmartinir.com
FAQ
What are the key findings of ZimVie's (ZIMV) new dental implant surface study?
How do ZimVie's (ZIMV) T3 PRO and TSX implants perform compared to competitors?
What technology does ZimVie (ZIMV) use in their dental implant surfaces?
What dental health issues does ZimVie's (ZIMV) implant technology address?
